IBRX
$8.21
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.
Recent News
ImmunityBio Highlights ANKTIVA Surge, FDA Papillary Filing and Key 2026 Milestones at Conference
ImmunityBio (NASDAQ:IBRX) CEO Richard Adcock used a presentation at the Citizens Life Sciences Conference to outline the company’s commercial progress with its lead product ANKTIVA and to highlight multiple upcoming regulatory and clinical milestones across bladder cancer, lung cancer, and earlier-s
The Stubborn Billionaire Behind the L.A. Times’s Revamp
Patrick Soon-Shiong is pursuing a public offering for the media company, while juggling healthcare and tech pursuits.
NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus
NCCN has added ImmunityBio's ANKTIVA to its Clinical Practice Guidelines for BCG-unresponsive non muscle invasive bladder cancer with papillary only disease. This update extends recognized use of ANKTIVA to a patient group that previously had fewer guideline supported options. NCCN guideline changes can influence oncologist prescribing patterns and payer decisions ahead of any FDA label update. For ImmunityBio (NasdaqGS:IBRX), this guideline expansion comes with the stock at $8.21 and very...
Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026?
IBRX's Anktiva fueled a 700% revenue surge in 2025, but can repeat prescriptions, global expansion and BCG shortages sustain momentum into 2026?
IBRX Stock Jumps on Progress in NK Cell Therapy Production
ImmunityBio stock gains more than 7% after completing two programs, showing scalable production of M-ceNK NK cells and early safety data in solid tumor patients.